Last edition
News about "Denosumab biosimilars"
Biocon Launches Bosaya and Aukelso Denosumab Biosimilars in US
Biocon launches Bosaya and Aukelso denosumab biosimilars in the US following FDA approval with interchangeable status, expanding treatment options for osteoporosis and bone metastasis patients.
Denosumab Biosimilars | 08/04/2026 | By News Bureau
Amneal Gains US FDA Approval for Prolia and XGEVA Denosumab Biosimilars
The US FDA approvals for Prolia and XGEVA denosumab biosimilars strengthen Amneal’s growing biosimilars portfolio, with the company planning to commercialise six biosimilars across eight presentations by 2027.
Denosumab Biosimilars | 23/12/2025 | By News Bureau | 177
Biocon Biologics Reaches Settlement with Amgen, Secures Market Entry Date for Denosumab Biosimilars
Biocon Biologics will introduce both its Denosumab biosimilars — Vevzuo and Evfraxy — in Europe beginning December 2, 2025. Other terms of the settlement with Amgen remain confidential.
Denosumab Biosimilars | 02/12/2025 | By Dineshwori
Biocon Biologics, Amgen Settle Patent Dispute, Paving Way for US Launch of Denosumab Biosimilars
The agreement with Amgen enables Biocon Biologics to launch denosumab biosimilars Bosaya and Aukelso in the US from October 1, 2025.
Denosumab Biosimilars | 01/10/2025 | By Dineshwori | 377
Biocon Biologics Secures US FDA Approval for Denosumab Biosimilars Bosaya and Aukelso
The US Food and Drug Administration (FDA) has approved Biocon Biologics' denosumab biosimilars, Bosaya (denosumab-kyqq) 60 mg/mL injection in a single-dose prefilled syringe (PFS) and Aukelso (denosumab-kyqq) 120 mg/1.7 mL (70 mg/mL) injection in a single-dose vial, biosimilars of Prolia and Xgeva, respectively.
Denosumab Biosimilars | 17/09/2025 | By Dineshwori | 425
Biocon Biologics Receives European Commission Nod for Denosumab Biosimilars to Improve Bone Health
Biocon Biologics has received European Commission approval for its Denosumab biosimilars, Vevzuo and Evfraxy, thereby expanding access to advanced treatments for bone-related conditions across the EU.
Denosumab Biosimilars | 03/07/2025 | By Mrinmoy Dey | 200
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy